Lack of interaction between tacrolimus (FK506) and methotrexate (MTX) in bone marrow transplant (BMT) recipients.

被引：0
|
作者：
Wingard, JR
Nash, RA
Ratanatharathorn, V
Fay, JW
Klein, JL
Przepiorka, D
Devine, SM
Fitzsimmons, WE
机构：
[1] FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104
[2] EMORY UNIV,ATLANTA,GA 30322
[3] WAYNE STATE UNIV,DETROIT,MI
[4] BAYLOR UNIV,MED CTR,DALLAS,TX
[5] OHIO STATE UNIV,COLUMBUS,OH 43210
[6] UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX
[7] FUJISAWA USA,DEERFIELD,IL
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1570 / 1570
页数：1
相关论文
共 50 条
  • [31] Eye Movement Disorders Following Allogeneic Bone Marrow Transplantation on FK506 (Tacrolimus) and Ganciclovir
    Karagun, Barbaros S.
    Akbas, Tugana
    Arpaci, Taner
    Antmen, Bulent
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (01) : 71 - 73
  • [32] Tacrolimus (FK506) nephrotoxicity in heart transplant recipients - A four-year follow-up
    Stempfle, HU
    Hien, M
    Wiescher, C
    Meiser, B
    Schrepf, R
    Reichart, B
    Theisen, K
    [J]. EUROPEAN HEART JOURNAL, 2001, 22 : 402 - 402
  • [33] Tacrolimus (FK506) versus cyclosporine microemulsion (Neoral) as maintenance immunosuppression therapy in kidney transplant recipients
    Abou-Jaoude, MM
    Najm, R
    Shaheen, J
    Nawfal, N
    Abboud, S
    AlHabash, M
    Darwish, M
    Mulhem, A
    Ojjeh, A
    Almawi, WY
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (07) : 3025 - 3028
  • [34] Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction
    Kramer, Mordechai R.
    Amital, Anat
    Fuks, Leonardo
    Shitrit, David
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 (02) : E163 - E167
  • [35] Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): Efficacy and drug interaction
    Shitrit, D
    Ollech, JE
    Ollech, A
    Bakal, I
    Saute, M
    Sahar, G
    Kramer, MR
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (12): : 2148 - 2152
  • [36] A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
    Zhengshan Wu
    Qingyang Meng
    Yongxiang Xia
    Feng Zhang
    Wei You
    [J]. The Journal of Biomedical Research, 2013, 27 (04) : 305 - 309
  • [37] A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
    Wu, Zhengshan
    Meng, Qingyang
    Xia, Yongxiang
    Zhang, Feng
    You, Wei
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2013, 27 (04): : 305 - 309
  • [38] Effect of conversion from cyclosporine A (CSA) to tacrolimus (FK 506) on cardiovascular risk factors in liver transplant recipients.
    Canzanello, VJ
    Schwartz, LL
    Taler, SJ
    Textor, SC
    Atwood, G
    Porayko, MK
    Wiesner, RH
    Krom, RAF
    [J]. HEPATOLOGY, 1997, 26 (04) : 1443 - 1443
  • [39] Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
    Cacciarelli, TV
    Green, M
    Jaffe, R
    Mazariegos, GV
    Jain, A
    Fung, JJ
    Reyes, J
    [J]. TRANSPLANTATION, 1998, 66 (08) : 1047 - 1052
  • [40] SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER-TRANSPLANT RECIPIENTS
    TEXTOR, SC
    WIESNER, R
    WILSON, DJ
    PORAYKO, M
    ROMERO, JC
    BURNETT, JC
    GORES, G
    HAY, E
    DICKSON, ER
    KROM, RA
    [J]. TRANSPLANTATION, 1993, 55 (06) : 1332 - 1339
12345